Metspot XL 25 Tablet is a controlled-release formulation containing Metoprolol Succinate, a beta-blocker, in a strength of 23.75mg per tablet. This medication is indicated for the treatment of hypertension, angina pectoris, and chronic heart failure. Metspot XL 25 Tablet is designed to provide a gradual release of the active ingredient over an extended period, thereby maintaining consistent therapeutic levels throughout the day. The therapeutic effects of Metspot XL 25 Tablet include reduced heart rate, blood pressure, and cardiac workload, as well as improved left ventricular function. The medication is contraindicated in patients with second- or third-degree atrioventricular block, sinus bradycardia, and severe peripheral arterial disease. Patients with a history of bronchospastic disease should be monitored closely for signs of bronchospasm, as Metspot XL 25 Tablet may exacerbate such conditions. The recommended starting dose is one tablet once daily, with adjustments as needed to achieve optimal therapeutic response.